KevinMatthewFlaniganMD

Neuromuscular Medicine

Director, Center for Gene Therapy, and Robert F. & Edgar T. Wolfe Foundation Endowed Chair in Neuromuscular Research, Nationwide Children’s Hospital; Professor of Pediatrics and Neurology at the Ohio State University College of Medicine

Join to view full profile

Dr. Flanigan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Flanigan's full profile

Already have an account?

Office
555 S 18th St
Columbus, OH 43205
Phone+1 614-722-6200

Education & Training

Johns Hopkins UniversityFellowship, Neuromuscular Medicine (Neurology), 1994 - 1995
Johns Hopkins UniversityResidency, Neurology, 1991 - 1994
University of MichiganInternship, Internal Medicine, 1990 - 1991
Rush Medical College of Rush University Medical CenterClass of 1990

Certifications & Licensure

OH State Medical License 2010 - 2027
UT State Medical License 1995 - 2010
MI State Medical License 1990 - 1991
American Board of Psychiatry and Neurology Neurology
American Board of Psychiatry and Neurology Neuromuscular Medicine

Clinical Trials

Finding the Optimum Regimen for Duchenne Muscular Dystrophy Start of enrollment: 2013 Jan 01
Completed
Phase 3
A Study of the Safety, Tolerability & Efficacy of Long-term Administration of Drisapersen in US & Canadian Subjects Start of enrollment: 2013 May 01
Terminated
Phase 3
Natural History Studies of Mucopolysaccharidosis III Start of enrollment: 2014 Feb 01
Completed
Gene Transfer Clinical Trial for Duchenne Muscular Dystrophy Using rAAVrh74.MCK.GALGT2 Start of enrollment: 2016 Apr 01
Withdrawn
Phase 1, Phase 2
Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSH Start of enrollment: 2016 Mar 01
Active, not recruiting
Phase 2, Phase 3
Gene Transfer Clinical Trial for Mucopolysaccharidosis (MPS) IIIB Start of enrollment: 2017 Oct 16
Terminated
Phase 1, Phase 2
Gene Transfer Clinical Trial to Deliver rAAVrh74.MCK.GALGT2 for Duchenne Muscular Dystrophy Start of enrollment: 2017 Nov 06
Active, not recruiting
Phase 1, Phase 2
Spironolactone Versus Prednisolone in DMD Start of enrollment: 2018 Dec 05
Terminated
Phase 1
A Long-term Follow-up Study of Patients With MPS IIIA Treated With ABO-102 Start of enrollment: 2020 Sep 28
Enrolling by invitation
Phase 3
Join now to see all

Publications & Presentations

PubMed

1 citations
Evaluation of safety and early efficacy of AAV gene therapy in mouse models of vanishing white matter disease.
Jessica A Herstine, Pi-Kai Chang, Sergiy Chornyy, Tamara J Stevenson, Alex C Sunshine
Molecular Therapy. 2024-06-05
1 citations
Increase in Full-Length Dystrophin by Exon Skipping in Duchenne Muscular Dystrophy Patients with Single Exon Duplications: An Open-label Study.
Stefan Nicolau, Jyoti Malhotra, Maryann Kaler, Pamela Magistrado-Coxen, Megan A Iammarino
Journal of Neuromuscular Diseases. 2024-01-01
2 citations
Persistence of exon 2 skipping and dystrophin expression at 18 months after U7snRNA-mediated therapy in the Dup2 mouse model.
Liubov V Gushchina, Adrienne J Bradley, Tatyana A Vetter, Jacob W Lay, Natalie L Rohan
Molecular Therapy. Methods & Clinical Development. 2023-12-14

Press Mentions

Nationwide Children's Names Gene Therapy Center for Retired Pioneer Dr. Jerry MendellSeptember 13th, 2024
Can Gene Editing Kill Deadly Diseases?April 11th, 2023
Muscular Dystrophy Association Virtual Conference to Feature Latest Advances in Neuromuscular Therapy and Clinical CareMarch 8th, 2021
Join now to see all